Standard chemotherapy with cetuximab for treatment of colorectal cancer

Table 1 Included studies on efficacy of cetuximab plus chemotherapy vs chemotherapy alone in patients with metastatic or advanced colorectal cancer

Study	Type of article	Patients	Intervention		Main endpoints	Mutation status reported		Quality control
			Cetuximab + chemotherapy	Chemotherapy	(HR, 95%CI)	KRAS	BRAF
Borner et al[27]	Full manuscript	74	Cetuximab + XELOX	XELOX	PFS: NR; OS: NR	No	No	Moderate
Bokemeyer et al[25]	Full manuscript	337	Cetuximab + FOLFOX-4	FOLFOX-4	PFS: 0.931, 0.705-1.230;	Yes	Yes	Good
					OS: 1.015, 0.791-1.303
Van Cutsem et al[21]	Full manuscript	1198	Cetuximab + FOLFIRI	FOLFIRI	PFS: 0.851, 0.726-0.998;	Yes	Yes	Good
					OS: 0.878, 0.774-0.995
Maughan et al[17]	Full manuscript	1630	Cetuximab + oxaliplatin + fluoropyrimidine	Oxaliplatin + fluoropyrimidine	PFS: 0.96, 0.82-1.12;	Yes	Yes	Good
					OS: 1.04, 0.87-1.23
Tveit et al[22]	Full manuscript	571	Cetuximab + FLOX	FLOX	PFS: NR; OS: NR	Yes	Yes	Good
Alberts et al[26]	Full manuscript	2686	Cetuximab + mFOLFOX6	mFOLFOX6	PFS: NR; OS: NR	Yes	Yes	Good
Huang et al[24]	Full manuscript	146	Cetuximab + FOLFIRI	FOLFIRI	PFS: 0.53, 0.26-1.10;	Yes	Yes	Good
					OS: 0.45, 0.2-1.2
Ye et al[23]	Full manuscript	138	Cetuximab + mFOLFOX6/ FOLFIRI	mFOLFOX6/	PFS: 0.60, 0.41-0.87;	Yes	Yes	Good
				FOLFIRI	OS: 0.54, 0.33-0.89

XELOX: Capecitabine and oxaliplatin regimen; FOLFOX-4: Oxaliplatin and folinic acid and 5-fluorouracil regimen; FOLFIRI: Fluorouracil and leucovorin and irinotecan regimen; FLOX: Fluorouracil/folinic acid and oxaliplatin regimen; mFOLFOX6: Oxaliplatin and leucovorin and fluorouracil regimen; PFS: Progression free survival; OS: Overall survival; NR: Not reported.

Table 2 Adverse events (grade 3 and 4)

Study	Neutropenia		Nausea and vomiting		Skin toxicity/rash		Rash		Diarrhea
	Control group	Cetuximab group	Control group	Cetuximab group	Control group	Cetuximab group	Control group	Cetuximab group	Control group	Cetuximab group
Borner et al[27]	3	0	6	10	0	16	0	8	16	22
Bokemeyer et al[25]	57	51	NA	NA	1	30	1	19	12	14
Van Cutsem et al[21]	150	169	30	28	1	117	0	49	63	94
Maughan et al[17]	NA	NA	NA	NA	14	114	NA	NA	NA	NA
Tveit et al[22]	47	95	3	14	1	51	1	51	10	33
Alberts et al[26]	89	110	59	70	NA	NA	3	186	83	148
Huang et al[24]	15	3	0	18	NA	NA	0	11	15	6
Ye et al[23]	6	8	3	3	1	2	2	9	3	4

GI: Gastrointestinal toxic effects; NA: Not available.